Peritoneal effusion: an uncommon adverse effect of selective RET inhibitors

Ann Oncol. 2024 May;35(5):478-480. doi: 10.1016/j.annonc.2024.02.004. Epub 2024 Feb 16.

Authors

C Belli¹, G Curigliano²

Affiliations

¹ Division of Early Drug Development for Innovative Therapy, European Institute of Oncology, IRCCS, Milan.
² Division of Early Drug Development for Innovative Therapy, European Institute of Oncology, IRCCS, Milan; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy. Electronic address: giuseppe.curigliano@ieo.it.

PMID: 38369014
DOI: 10.1016/j.annonc.2024.02.004

No abstract available

Publication types

Letter
Case Reports

MeSH terms

Female
Humans
Male
Middle Aged
Phenylurea Compounds / adverse effects
Protein Kinase Inhibitors / adverse effects
Proto-Oncogene Proteins c-ret* / antagonists & inhibitors
Proto-Oncogene Proteins c-ret* / genetics
Pyrazoles*
Pyridines / adverse effects

Substances

Proto-Oncogene Proteins c-ret
RET protein, human
Protein Kinase Inhibitors
Pyridines
selpercatinib
Phenylurea Compounds
Pyrazoles